CT Atlantic: Reverse translation

Reverse translational medicine, the practice of developing therapeutics by studying patients who have a less severe disease state than others, has governed the development of vaccines against infectious disease for two centuries. CT Atlantic AG is applying the strategy to the identification and development of human antibodies to treat cancer.

The company, which spun out from the University of Zurich and The Ludwig Institute for Cancer Research last year, seeks patients with slower disease progression that suggests their immune systems are fighting off disease, then isolates and identifies the antibodies that could be responsible...